๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—† Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity โ—† Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing โ—† Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich โ—† Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery โ—† Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma โ—† Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide โ—† The โ‚ฌ100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany โ—† Ireland's โ‚ฌ93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact โ—†
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Melbourne
Clinical trial register · Australia

Clinical Trials in Melbourne, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 3335 matching records held by the registry are in this view. Synced 30 Sep 2026, 03:17 UTC
3335
Studies in scope
all four open statuses
1809
Recruiting now
open to new participants
761
Lead sponsors
across recruiting studies
Top sites
Westmead 17 Brisbane 15 Melbourne 13 Clayton 11 Camperdown 11
Narrow the registerReset
Recruitment status
Phase
Site location
Westmead17 Brisbane15 Melbourne13 Clayton11 Camperdown11
All 74 locations
Target enrolment
to

Trials with a site in Melbourne

13 of 3335 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Not yet open
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
NCT07284745Irritability Associated With Autism Spectrum Disorder
Bristol-Myers Squibb
Phase 3
176
Westmead, Brisbane, Melbourne
2026-09-11
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
Liverpool, Birtinya, Elizabeth Vale, Clayton, Melbourne, Murdoch
2026-03-13
Recruiting
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
NCT06408259Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb
Phase 3
194
Melbourne
2025-04-08
Recruiting
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT06618287Lung Cancer, Breast Cancer
Bristol-Myers Squibb
Phase 1/2
416
Liverpool, Woolloongabba, Melbourne, Subiaco
2025-02-04
Active, closed
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
NCT06268886Alzheimer Disease, Early Onset
Bristol-Myers Squibb
Phase 2
310
East Gosford, Macquarie Park, Griffith University, Carlton North, Ivanhoe, Malvern, Melbourne, Parkville
2024-03-20
Active, closed
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743Cardiomyopathy, Hypertrophic
Bristol-Myers Squibb
Phase 4
63
Camperdown, Chermside, Melbourne
2024-01-24
Active, closed
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
NCT04857034Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous
Bristol-Myers Squibb
Phase 2
74
Botany, Kogarah, Camberwell, Clayton, Melbourne, Victoria Park
2021-07-12
Recruiting
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
Bristol-Myers Squibb
Phase 1/2
1,109
Blacktown, Liverpool, Brisbane, Malvern, Melbourne, Nedlands
2021-05-27
Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
NCT04772079Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
153
Darlinghurst, Westmead, Brisbane, Woolloongabba, Clayton, Melbourne
2021-03-23
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 1 October 2026. https://priyalifescience.com/clinical-trials-australia/city/melbourne

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,335 studies in total at the last sync on 30 Sep 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Melbourne that also match the filters currently applied.

How many clinical trials are recruiting in Melbourne?

6 of the 13 studies on this page are recruiting new participants as of the 30 Sep 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Melbourne), 13 studies
PhaseStudiesRecruitingShare
Phase 2/34230.8%
Phase 34230.8%
Phase 1/22215.4%
Phase 22015.4%
Phase 4107.7%

Most active sponsors

Lead sponsors with the most studies (Melbourne)
Lead sponsorStudiesRecruiting
Bristol-Myers Squibb136
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.